Pacific Biosciences Of California (PACB) EBIT Margin (2010 - 2026)

Pacific Biosciences Of California's EBIT Margin history runs 17 years deep, the most recent figure standing at 22.48% for Q1 2026.

• In Q1 2026, EBIT Margin rose 113203.0% year-over-year to 22.48%; the TTM figure through Mar 2026 stood at 83.29% (up 45616.0% YoY), while the FY2025 annual figure was 346.15%, down 3818.0% from the prior year.
• EBIT Margin was 22.48% for Q1 2026 at Pacific Biosciences Of California, up from 92.28% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 22.48% in Q1 2026 to a low of 1154.51% in Q1 2025.
• Historically, EBIT Margin has averaged 258.4% across 5 years, with a median of 191.64% in 2022.
• The sharpest annual moves came in 2025 and 2026: EBIT Margin plunged 94487 bps in 2025, then soared 113203 bps in 2026.
• A 5-year view of EBIT Margin shows it stood at 318.37% in 2022, then surged by 53 bps to 150.02% in 2023, then sank by 160 bps to 390.14% in 2024, then soared by 76 bps to 92.28% in 2025, then jumped by 76 bps to 22.48% in 2026.
• The last three EBIT Margin figures came in at 22.48% (Q1 2026), 92.28% (Q4 2025), and 101.13% (Q3 2025), per Business Quant data.